Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04521114 · ClinicalTrials.gov registry record · Phase 2
Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis
A Phase 2 study, sponsored by CytoDyn.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT04521114 is a Phase 2 study that has completed, run by CytoDyn. The registered enrollment target is 87 participants.
The verdict
NCT04521114, a Phase 2 study, has completed, sponsored by CytoDyn.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
This is a phase II study of of Leronlimab (PRO 140)-Humanized monoclonal antibody to CCR5 in patients with Nonalcoholic Steatohepatitis (NASH).
Interventions
- DRUG Placebo
- DRUG leronlimab 700 mg
- DRUG leronlimab 350 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2021-12-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04521114
The ClinicalTrials.gov registry entry for NCT04521114 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoDyn, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04521114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04521114 about?
NCT04521114 is a clinical study titled "Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis". This is a phase II study of of Leronlimab (PRO 140)-Humanized monoclonal antibody to CCR5 in patients with Nonalcoholic Steatohepatitis (NASH).
What is the current status of trial NCT04521114?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2020-12-01. Estimated completion is 2021-12-29.
What interventions are being tested in trial NCT04521114?
The interventions under investigation include: Placebo (DRUG), leronlimab 700 mg (DRUG), leronlimab 350 mg (DRUG).
Who is sponsoring clinical trial NCT04521114?
This trial is sponsored by CytoDyn, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.